"If there are important results to present on CKD and/or cognitive function, my expectation is that these academics will want to present them at the meetings in their particular specialty, not at the AHA.....You also have to keep in mind that 8 minutes is not long to give a slide presentation.....S..squeezing in results on CKD, ALP, and/or cognitive function might be impossible even they wanted to!"

For the timing of CKD sub-study presentation, the problem with the above logic is that there are only two main kidney meetings each year that I know of: ASN November 5-10 and then ERA-EDTA in June. Since this is dealing with diabetic CKD, this could also fit with American Diabetes Association annual meeting, but that is also in June. What other kidney meetings do you know of?

There is a ton of focus on alkaline phosphatase at ASN and AHA, which ties into the kidney story. Put it all together and it's either ASN or AHA in November for presenting CKD sub-study in 2019 at a conference, or it's June 2020. I find it highly unlikely for Resverlogix to wait until 2020 to present and/or announce CKD sub-study results. If not a conference presentation at AHA or ASN,  then I expect they announce the semi-detailed results (not just top-line) via news release around the time of ASN or AHA, or shortly after AHA. It can still be presented in even more detail at a kidney conference in 2020. 

For the cognition sub-study, it is pretty clear that Dr. Jeffrey Cummings will be presenting the cognition sub-study results in December at Clinical Trials on Alzheimer's Disease (CTAD). Again, Resverlogix could still release top-line or semi-detailed results via news release prior to CTAD.

PRESENTER 4: Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

BDAZ